I-MAT
07 Jun 2021
Trial Summary
The I-MAT trial is a randomised, placebo-controlled, phase II trial of adjuvant Avelumab in patients with stage I-III Merkel cell carcinoma aiming to explore the efficacy of avelumab as adjuvant immunotherapy.
Acronym:
I-MAT
ACTRN/NCT /ethics:
NCT04291885
Scientific title:
A randomised, placebo-controlled, phase II trial of adjuvant Avelumab in patients with stage I-III Merkel cell carcinoma. I-MAT ( 03.18)
Sponsor / Cooperative group:
Melanoma and Skin Cancer Trials Limited
Trial & Patient Characteristics
| Cancer Type | Melanoma & other skin |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | All stages |
| Anticipated Start Date | 2020-10-08 |
| Anticipated End Date | 2028-12-01 |
Participating Hospitals
| Hospital | Royal Adelaide Hospital |
|---|---|
| Clinical Trial Coordinator | Anne Milton |
| anne.milton@sa.gov.au | |
| Phone | 08 7074 2342 |
| Principal Investigator | Professor Michael Brown |
| Recruitment Status | Recruiting |